Radioimmunotherapy of Neuroblastoma

  • Shakeel Modak
  • Kim Kramer
  • Neeta Pandit-Taskar
Part of the Medical Radiology book series (MEDRAD)


Effecting cures in patients with neuroblastoma remains a major challenge despite aggressive multimodality therapy. Antibody-mediated anti-GD2 immunotherapy has recently been shown to improve survival and is now considered part of frontline therapy for high-risk neuroblastoma. Radioimmunotherapy has the potential to target effective radiation to neuroblastoma, at the same time avoiding the toxicities of external beam radiotherapy which are often severe in children. The anti-GD2 radiolabeled antibodies 131I-3F8 and 131I-14G2a have been shown to target neuroblastoma and have been used for radioimmunodetection and are more specific and sensitive at detecting disease than 131I-MIBG. Toxicities, biodistribution and dosimetry for intravenous 131I-3F8 have been determined in phase I and II trials in patients with neuroblastoma. Myelosuppression, reversible with hematopoietic stem cell rescue is a major toxicity. Patients also experienced pain and allergic reactions. 131I-3F8 has been injected into the ventricles via Ommaya injection in leptomeningeal neuroblastoma without long-term toxicities being observed. Intra-Ommaya anti-4Ig-B7H3 radiolabeled monoclonal antibody 131I-8H9 is also being studied in a phase I study for patients with leptomeningeal disease. Radioimmunotherapy with both radioiodinated antibodies is a key component of a therapeutic regimen for relapsed leptomeningeal neuroblastoma which has resulted in encouraging long-term survival rates in a majority of patients with this hitherto uniformly lethal disease. Detailed dosimetry information and high-quality images have been acquired via PET imaging after intra-Ommaya injections of the radioimmunoconjugates 124I-3F8 and 124I-8H9. The recent availability of humanized versions of 3F8 and 8H9 may permit the clinical study of newer and potentially more effective radioimmunoconjugates for the radioimmunotherapy of neuroblastoma. However, for the expanded clinical investigation of radioimmunotherapy and its inclusion in the armamentarium of therapies for neuroblastoma and other “orphan” pediatric malignancies, major policy changes in drug development strategies are necessary.


Minimal Residual Disease Central Nervous System Relapse Desmoplastic Small Round Cell Tumor Pediatric Solid Tumor Autologous Stem Cell Rescue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Blatt J, Fitz C, Mirro J (1997) Recognition of central nervous system metastasesin children with metastatic primary extracranial neuroblastoma. Pediatr Hematol Oncol 14:233–241PubMedCrossRefGoogle Scholar
  2. Bullens RW, O’Hanlon GM, Wagner E et al (2003) Roles of complex gangliosides at the neuromuscular junction. Ann N Y Acad Sci 998:401–403PubMedCrossRefGoogle Scholar
  3. Carpenter EL, Haglund EA, Mace EM et al (2012) Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene 31:4859–4867PubMedCentralPubMedCrossRefGoogle Scholar
  4. Caussa L, Hijal T, Michon J, Helfre S (2011) Role of palliative radiotherapy in the management of metastatic pediatric neuroblastoma: a retrospective single-institution study. Int J Radiat Oncol Biol Phys 79:214–219PubMedCrossRefGoogle Scholar
  5. Chapoval AI, Ni J, Lau JS et al (2001) B7–H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2:269–274PubMedCrossRefGoogle Scholar
  6. Chen YW, Tekle C, Fodstad O (2008) The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr Cancer Drug Targets 8:404–413PubMedCrossRefGoogle Scholar
  7. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF (1985) Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45:2642–2649PubMedGoogle Scholar
  8. Cheung NK, Lazarus H, Miraldi FD et al (1987) Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430–1440PubMedGoogle Scholar
  9. Cheung NK, Munn D, Kushner BH, Usmani N, Yeh SD (1989) Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies. Int J Rad Appl Instrum B 16:111–120PubMedCrossRefGoogle Scholar
  10. Cheung NK, Pentlow K, Graham MC, Yeh SDJ, Finn RD, Larson SM (1992) Radioimmunotherapy of human neuroblastoma using monoclonal antibody 3F8. Fifth international radiopharmaceutical dosimetry symposium, Oak Ridge,1992. Oak Ridge Associated Universities, Tennessee, pp 95–112Google Scholar
  11. Cheung NK, Kushner BH, Cheung IY et al (1998) Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 16:3053–3060PubMedGoogle Scholar
  12. Cheung NK, Kushner BH, Kramer K (2001a) Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am 15:853–866PubMedCrossRefGoogle Scholar
  13. Cheung NK, Kushner BH, LaQuaglia M et al (2001b) N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 36:227–230PubMedCrossRefGoogle Scholar
  14. Cheung N-KV, Modak S, Lin YK et al (2004) Single chain Fv-streptavidin substantially improved therapeutic index in multi-step targeting directed at disialoganglioside GD2. J Nucl Med 45:867–877PubMedGoogle Scholar
  15. Cheung NK, Zhang J, Lu C et al (2012a) Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307:1062–1071PubMedCentralPubMedCrossRefGoogle Scholar
  16. Cheung NK, Cheung IY, Kushner BH et al (2012b) Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol 30:3264–3270PubMedCentralPubMedCrossRefGoogle Scholar
  17. Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY (2012c) Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 1:477–486PubMedCentralPubMedCrossRefGoogle Scholar
  18. Croog VJ, Kramer K, Cheung NK et al (2010) Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 78:849–854PubMedCrossRefGoogle Scholar
  19. Daghighian F, Pentlow KS, Larson SM et al (1993) Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med 20:402–409PubMedCrossRefGoogle Scholar
  20. Dauer LT, Germain J, Williamson MJ et al (2007) Whole-body clearance kinetics and external dosimetry of 131I–3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma. Health Phys 92:33–39PubMedCrossRefGoogle Scholar
  21. DuBois SG, Matthay KK (2008) Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 35(Suppl 1):S35–S48PubMedCentralPubMedCrossRefGoogle Scholar
  22. DuBois SG, Kalika Y, Lukens JN et al (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21:181–189PubMedCrossRefGoogle Scholar
  23. Flies DB, Chen L (2007) The new B7 s: playing a pivotal role in tumor immunity. J Immunother 30:251–260PubMedCrossRefGoogle Scholar
  24. Furukawa K, Soejima H, Niikawa N, Shiku H (1996) Genomic organization and chromosomal assignment of the human B1,4-N-acetylgalactosaminyltransferase gene. J Biol Chem 271:20836–20844PubMedCrossRefGoogle Scholar
  25. Gains JE, Bomanji JB, Fersht NL et al (2011) 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med 52:1041–1047PubMedCrossRefGoogle Scholar
  26. George RE, Sanda T, Hanna M et al (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975–978PubMedCentralPubMedCrossRefGoogle Scholar
  27. Gillies SD, Lo K-M, Wesolowski J (1989) High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods 125:191–202PubMedCrossRefGoogle Scholar
  28. Goodman MT, Gurney JG, Smith MA, Olshan AF (2008) SEER pediatric monograph sympathetic nervous system tumors. National Cancer Institute, Bethesda, pp 65–72Google Scholar
  29. Hakomori S, Igarashi Y (1995) Functional role of glycosphingolipids in cell recognition and signaling. J Biochem (Tokyo) 118:1091–1103Google Scholar
  30. Heiner J, Miraldi FD, Kallick S et al (1987) Localization of GD2 specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res 47:5377–5381PubMedGoogle Scholar
  31. Helling F, Livingston PO (1994) Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin. Mol Chem Neuropathol 21:299–309PubMedCrossRefGoogle Scholar
  32. Hoefnagel CA, Rutgers M, Buitenhuis CK et al (2001) A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients. Eur J Nucl Med 28:359–368CrossRefGoogle Scholar
  33. Houghton PJ, Morton CL, Gorlick R et al (2010) Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program. Pediatr Blood Cancer 54:921–926PubMedCentralPubMedGoogle Scholar
  34. Kailayangiri S, Altvater B, Meltzer J et al (2012) The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer 106:1123–1133PubMedCentralPubMedCrossRefGoogle Scholar
  35. Kellie SJ, Hayes FA, Bowman L et al (1991) Primary extracranial neuroblastoma with central nervous system metastases characterization by clinicopathologic findings and neuroimaging. Cancer 68:1999–2006PubMedCrossRefGoogle Scholar
  36. Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK (2001a) Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Med Pediatr Oncol 36:194–196PubMedCrossRefGoogle Scholar
  37. Kramer K, Kushner B, Heller G, Cheung NK (2001b) Neuroblastoma metastatic to the central nervous system. The memorial Sloan-Kettering Cancer Center experience and a literature review. Cancer 91:1510–1519PubMedCrossRefGoogle Scholar
  38. Kramer K, Humm JL, Souweidane MM et al (2007) Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-ommaya 131-I-3F8. J Clin Oncol 25:5465–5470PubMedCrossRefGoogle Scholar
  39. Kramer K, Kushner BH, Modak S et al (2010) Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol 97:409–418PubMedCentralPubMedCrossRefGoogle Scholar
  40. Kushner BH, Cheung NK (1989) GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73:1936–1941PubMedGoogle Scholar
  41. Kushner BH, Wolden S, LaQuaglia MP et al (2001a) Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 19:2821–2828PubMedGoogle Scholar
  42. Kushner BH, Kramer K, Cheung NK (2001b) Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19:4189–4194PubMedGoogle Scholar
  43. Kushner BH, Kramer K, Modak S, Cheung NK (2004) Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clin Cancer Res 10:84–87PubMedCrossRefGoogle Scholar
  44. Kushner BH, Kramer K, Modak S et al (2006) Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system. Bone Marrow Transpl 37:271–276CrossRefGoogle Scholar
  45. Kushner BH, Cheung IY, Kramer K, Modak S, Cheung NK (2007) High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Pediatr Blood Cancer 48:430–434PubMedCrossRefGoogle Scholar
  46. Kushner BH, Cheung NK, Barker CA et al (2009) Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 75:1181–1186PubMedCrossRefGoogle Scholar
  47. Larson SM, Pentlow KS, Volkow ND et al (1992) PET scanning of iodine-124-3F8 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 33:2020–2023PubMedGoogle Scholar
  48. Larson SM, Divgi C, Sgouros G, Cheung NKC, Scheinberg DA (2000) Monoclonal antibodies: basic prniciples—Radioisotope conjugates. In: DeVita VT, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer—principles and practice. J.B. Lippincott Co, Philadelphia, pp 396–412Google Scholar
  49. Laverdiere C, Cheung NK, Kushner BH et al (2005) Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 45:324–332PubMedCrossRefGoogle Scholar
  50. Matthay KK, Brisse H, Couanet D et al (2003) Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer 98:155–165PubMedCrossRefGoogle Scholar
  51. Matthay KK, Reynolds CP, Seeger RC et al (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol 27:1007–1013PubMedCentralPubMedCrossRefGoogle Scholar
  52. Menda Y, O’Dorisio MS, Kao S et al (2010) Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med 51:1524–1531PubMedCentralPubMedCrossRefGoogle Scholar
  53. Miederer M, McDevitt MR, Borchardt P et al (2004) Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res 10:6985–6992PubMedCrossRefGoogle Scholar
  54. Modak S, Cheung NK (2005) Antibody-based targeted radiation to pediatric tumors. J Nucl Med 46(Suppl 1):157S–163SPubMedGoogle Scholar
  55. Modak S, Cheung NK (2007) Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 25:67–77PubMedCrossRefGoogle Scholar
  56. Modak S, Cheung NK (2010) Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev 36:307–317PubMedCrossRefGoogle Scholar
  57. Modak S, Kramer K, Gultekin SH, Guo HF, Cheung NK (2001) Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 61:4048–4054PubMedGoogle Scholar
  58. Modak S, Gerald W, Cheung NK (2002) Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor. Med Pediatr Oncol 39:547–551PubMedCrossRefGoogle Scholar
  59. Modak S, Guo HF, Humm JL, Smith-Jones PM, Larson SM, Cheung NK (2005) Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9. Cancer Biother Radiopharm 20:534–546PubMedCrossRefGoogle Scholar
  60. Modak S, Chung J, Cheung NK (2006) Targeting of vascular endothelial growth factor (VEGF) synergizes with 131I-3F8 in radioimmunotherapy of human neuroblastoma. Proc AACR 47:571 (abs)Google Scholar
  61. Modak S, Kushner BH, LaQuaglia MP, Kramer K, Cheung NK (2009) Management and outcome of stage 3 neuroblastoma. Eur J Cancer 45:90–98PubMedCentralPubMedCrossRefGoogle Scholar
  62. Modak S, Kushner BH, Kramer K et al (2010) Combined radioimmunotherapy and anti-angiogenic therapy for resistant neuroblastoma. Adv Neuroblastoma Res 137 (abs SEL12)Google Scholar
  63. Mosse YP, Laudenslager M, Longo L et al (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455:930–935PubMedCentralPubMedCrossRefGoogle Scholar
  64. Munn DH, Cheung NK (1987) Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity (ADCC) against human melanoma. Cancer Res 47:6600–6605PubMedGoogle Scholar
  65. Munn DH, Cheung NK (1989) Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays. J Exp Med 170:511–526PubMedCrossRefGoogle Scholar
  66. Murray JL, Cunningham JE, Brewer H et al (1994) Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12:184–193PubMedGoogle Scholar
  67. Navid F, Santana VM, Barfield RC (2010) Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets 10:200–209PubMedCentralPubMedCrossRefGoogle Scholar
  68. Novak-Hofer I, Amstutz HP, Haldemann A et al (1992) Radioimmunolocalization of neuroblastoma xenografts with chimeric antibody chCE7. J Nucl Med 33:231–236PubMedGoogle Scholar
  69. Ozkaynak MF, Sondel PM, Krailo MD et al (2000) Phase I study of chimeric human/murine antiganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma inmmediately after hematopoietic stem-cell transplantation: a Children’s Cancer Group Study. J Clin Oncol 2000(18):4077–4085Google Scholar
  70. Pearson AD, Pinkerton CR, Lewis IJ et al (2008) High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 9:247–256PubMedCrossRefGoogle Scholar
  71. Pentlow KS, Graham MC, Lambrecht RM, Cheung NKV, Larson SM (1991) Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys 18:357–366PubMedCrossRefGoogle Scholar
  72. Rebagay G, Yan S, Liu C, Cheung NK (2012) ROR1 and ROR2 in human malignancies: potentials for targeted therapy. Front Oncol 2:34PubMedCentralPubMedCrossRefGoogle Scholar
  73. Reuland P, Geiger L, Thelen MH et al (2001) Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response. J Pediatr Hematol Oncol 23:437–442PubMedCrossRefGoogle Scholar
  74. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA (1984) Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44:5914–5920PubMedGoogle Scholar
  75. Schwab M, Alitalo K, Klempnauer K-H et al (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and neuroblastoma tumor. Nature 305:245–248PubMedCrossRefGoogle Scholar
  76. Shaw PJ, Eden T (1992) Neuroblastoma with intracranial involvement: an ENSG study. Med Pediatr Oncol 20:149–155PubMedCrossRefGoogle Scholar
  77. Shusterman S, London WB, Gillies SD et al (2010) Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children’s Oncology Group (COG) phase II study. J Clin Oncol 28:4969–4975PubMedCentralPubMedCrossRefGoogle Scholar
  78. Strother DR, London WB, Schmidt ML et al (2012) Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of children’s oncology group study P9641. J Clin Oncol 30:1842–1848PubMedCentralPubMedCrossRefGoogle Scholar
  79. Sun M, Richards S, Prasad DV, Mai XM, Rudensky A, Dong C (2002) Characterization of mouse and human B7–H3 genes. J Immunol 168:6294–6297PubMedCrossRefGoogle Scholar
  80. Sun X, Vale M, Leung E, Kanwar JR, Gupta R, Krissansen GW (2003) Mouse B7–H3 induces antitumor immunity. Gene Ther 10:1728–1734PubMedCrossRefGoogle Scholar
  81. Vines EF, Le Pechoux C, Arriagada R (2003) Prophylactic cranial irradiation in small cell lung cancer. Semin Oncol 30:38–46PubMedCrossRefGoogle Scholar
  82. Wu Z, Schwartz E, Seeger RC, Ladisch S (1986) Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 46:440–443PubMedGoogle Scholar
  83. Xu H, Cheung IY, Guo HF, Cheung NK (2009) MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune-based therapy of human solid tumors. Cancer Res 69:6275–6281Google Scholar
  84. Yeh SD, Larson SM, Burch L et al (1991) Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine (MIBG) and standard diagnostic modalities. J Nucl Med 32:769–776PubMedGoogle Scholar
  85. Yu AL, Gilman AL, Ozkaynak MF et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324–1334PubMedCentralPubMedCrossRefGoogle Scholar
  86. Zanzonico PB, Siegel JA, Germain J (2000) A generalized algorithm for determining the time of release and the duration of post-release radiation precautions following radionuclide therapy. Health Phys 78:648–659PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Shakeel Modak
    • 1
  • Kim Kramer
    • 1
  • Neeta Pandit-Taskar
    • 2
  1. 1.Departments of PediatricsMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Departments of RadiologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations